Parkinson Disease Neuroprotection Clinical Trial
Daniel D Truong
Parkinson s And Movement Disorder Inst Box 1428, 2801 Atlantic Ave Long Beach, Ca 90806
Grant 1U10NS053387-01 from National Institute Of Neurological Disorders And Stroke IRG: ZNS1
Abstract: This is an application to join a multi-center trial collaboration to test potential neuroprotective agents in Parkinson s disease. The specific protocol and study design will be developed by the steering committee by which all sites will abide. We are a Research Institute consisting of a President and Clinical Director, 5 Investigators, 4 Research Coordinators and 1 Business Administrator who handles marketing, patient recruitment and human resources. We have conducted over 20 clinical trials (Phases IB, II, III and IV) involving various stages of Parkinson s disease and other neurological conditions, including Restless Leg Syndrome, dystonia, tremor, myoclonus, multiple sclerosis, and diabetic neuropathy. In the trials involving Parkinson s disease, we have met and/or exceed enrollment expectations. In six of these, we were the highest enroller and/or in the top 20% of all sites regarding enrollment. At our institute location adjacent to the Orange Coast Memorial Medical Center, we have six patient exam rooms, one large research room dedicated to clinical trials, one room for phlebotomy/drug storage/equipment, countertop centrifuge, refrigerated centrifuge, ECG machine, sphingmometers, light box for viewing films/X-rays, EMG machine, one subzero freezer (-40 degrees), 2 refrigerator/freezers, a waiting room, video, and television. There is a mutli-level parking facility next to the hospital with cafeteria.
Keywords: Parkinson s disease, clinical trial, neuroprotectant, X ray, brain, caregiver, cell, clinical trial phase II, clinical trial phase III, conditioning, diabetic neuropathy, drug preservation, dystonia, emotion, experimental design, family, health, hospital, human, lighting, multiple sclerosis, myoclonus, phlebotomy, pigment, restless legs syndrome, substantia nigra, television, tremor, clinical research
Project start date: 2007-02-15
Project end date: 2011-11-30
1U10NS053387-01 (2007): $52850
Sponsored Links Excellgen http://Excellgen.com
Grants awarded to Daniel D Truong
PARKINSON DISEASE NEUROPROTECTION CLINICAL TRIAL
Daniel D Truong
Long Beach Memorial Medical Center, 2801 Atlantic Ave, Long Beach, Ca 90806
Grant 3U10NS053387-04S1 from National Institute Of Neurological Disorders And Stroke
Abstract: This is an application to join a multi-center trial collaboration to test potential neuroprotective agents in Parkinson´s disease. The specific protocol and study design will be developed by the steering committee by which all sites will abide. We are a Research Institute consisting of a President and Clinical Director, 5 Investigators, 4 Research Coordinators and 1 Business Administrator who handles marketing, patient recruitment and human resources. We have conducted over 20 clinical trials (Phases IB, II, III and IV) involving various stages of Parkinson´s disease and other neurological conditions, including Restless Leg Syndrome, dystonia, tremor, myoclonus, multiple sclerosis, and diabetic neuropathy. In the trials involving Parkinson´s disease, we have met and/or exceed enrollment expectations. In six of these, we were the highest enroller and/or in the top 20% of all sites regarding enrollment. At our institute location adjacent to the Orange Coast Memorial Medical Center, we have six patient exam rooms, one large research room dedicated to clinical trials, one room for phlebotomy/drug storage/equipment, countertop centrifuge, refrigerated centrifuge, ECG machine, sphingmometers, light box for viewing films/X-rays, EMG machine, one subzero freezer (-40 degrees), 2 refrigerator/freezers, a waiting room, video, and television. There is a mutli-level parking facility next to the hospital with cafeteria
Keywords: Administrator; Affect; Boxing; Brain; Businesses; Care Givers; Caregivers; Cell Nucleus; Cells; Clinical; Clinical Trials; Clinical Trials, Phase III; Clinical Trials, Unspecified; Collaborations; Diabetic Neuropathies; Diagnosis; Doctor of Medicine; Drug Storage; Dysfunction; Dystonia; ECG; EKG; Ekbom Syndrome; Electrocardiogram; Electrocardiography; Encephalon; Encephalons; Enrollment; Equipment; Functional disorder; Goals; HOSP; Health; Hospitals; Human Resources; Idiopathic Parkinson Disease; Institutes; Investigators; Lewy Body Parkinson Disease; Light; Location; M.D.; MS (Multiple Sclerosis); Manpower; Marketing; Medical center; Multiple Sclerosis; Muscle Dystonia; Myoclonic Jerk; Myoclonus; Nervous System, Brain; Neurologic; Neurological; Neuroprotectants; Neuroprotective Agents; Neuroprotective Drugs; Nucleus; Oranges; Paralysis Agitans; Parking Facilities; Parkinson; Parkinson Disease; Parkinson`s; Parkinson`s disease; Parkinsons disease; Patient Recruitments; Patients; Phase; Phase 3 Clinical Trials; Phase III Clinical Trials; Phlebotomy; Photoradiation; Physiopathology; Pigments; Primary Parkinsonism; Protocol; Protocols documentation; Radiographic Film; Research; Research Design; Research Institute; Research Personnel; Researchers; Restless Legs; Restless Legs Syndrome; Sclerosis, Disseminated; Site; Staging; Study Type; Substantia Nigra; Substantia nigra structure; Symptoms; TV; Television; Testing; Tremor; Venous blood sampling; X-Ray Film; Xray Film; clinical investigation; diabetes-associated neuropathy; enroll; expectation; health related quality of life; improved; insular sclerosis; meetings; neuron cell death; neuron loss; neuronal cell death; neuronal loss; neuroprotection; pathophysiology; personnel; phase 3 study; phase 3 trial; phase III trial; prevent; preventing; protocol, phase III; study design; study, phase III
Project start date: 2007-02-15
Project end date: 2010-11-30
Budget start date: 1-DEC-2009
Budget end date: 30-NOV-2010
PFA/PA: RFA-NS-05-004
3U10NS053387-04S1 (2010): $42600
5U10NS053387-04 (2010): $55151